Cargando…

De novo gene signature identification from single‐cell RNA‐seq with hierarchical Poisson factorization

Common approaches to gene signature discovery in single‐cell RNA‐sequencing (scRNA‐seq) depend upon predefined structures like clusters or pseudo‐temporal order, require prior normalization, or do not account for the sparsity of single‐cell data. We present single‐cell hierarchical Poisson factoriza...

Descripción completa

Detalles Bibliográficos
Autores principales: Levitin, Hanna Mendes, Yuan, Jinzhou, Cheng, Yim Ling, Ruiz, Francisco JR, Bush, Erin C, Bruce, Jeffrey N, Canoll, Peter, Iavarone, Antonio, Lasorella, Anna, Blei, David M, Sims, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386217/
https://www.ncbi.nlm.nih.gov/pubmed/30796088
http://dx.doi.org/10.15252/msb.20188557
Descripción
Sumario:Common approaches to gene signature discovery in single‐cell RNA‐sequencing (scRNA‐seq) depend upon predefined structures like clusters or pseudo‐temporal order, require prior normalization, or do not account for the sparsity of single‐cell data. We present single‐cell hierarchical Poisson factorization (scHPF), a Bayesian factorization method that adapts hierarchical Poisson factorization (Gopalan et al, 2015, Proceedings of the 31st Conference on Uncertainty in Artificial Intelligence, 326) for de novo discovery of both continuous and discrete expression patterns from scRNA‐seq. scHPF does not require prior normalization and captures statistical properties of single‐cell data better than other methods in benchmark datasets. Applied to scRNA‐seq of the core and margin of a high‐grade glioma, scHPF uncovers marked differences in the abundance of glioma subpopulations across tumor regions and regionally associated expression biases within glioma subpopulations. scHFP revealed an expression signature that was spatially biased toward the glioma‐infiltrated margins and associated with inferior survival in glioblastoma.